The Brain, Neurological Features and Neuropsychological Functioning in Adults With Phenylketonuria: A Pilot Study
| Status: | Recruiting |
|---|---|
| Conditions: | Endocrine |
| Therapuetic Areas: | Endocrinology |
| Healthy: | No |
| Age Range: | 18 - 55 |
| Updated: | 5/5/2014 |
| Start Date: | August 2013 |
| Contact: | Vera Anastasoaie |
| Email: | vera.anastasoaie@childrens.harvard.edu |
| Phone: | 617 355-7346 |
Newborn screening and early treatment prevent the most severe manifestations of
phenylketonuria (PKU). However, executive functioning deficits, attention deficit disorder,
slow processing speed, and visual-motor problems commonly occur. Many adults with this
disorder also suffer depression and anxiety. Using advanced electroencephalogram (EEG) and
magnetic resonance imaging (MRI) techniques, including novel MR spectroscopy (MRS) we hope
to discover why this distinct constellation of deficits occurs in PKU. Adult subjects with
PKU will undergo EEG and comprehensive MRI evaluations, including a novel method of MR
spectroscopy to determine brain phenylalanine levels. In addition, they will receive
neurological and neuropsychological examinations and dietary evaluation.
phenylketonuria (PKU). However, executive functioning deficits, attention deficit disorder,
slow processing speed, and visual-motor problems commonly occur. Many adults with this
disorder also suffer depression and anxiety. Using advanced electroencephalogram (EEG) and
magnetic resonance imaging (MRI) techniques, including novel MR spectroscopy (MRS) we hope
to discover why this distinct constellation of deficits occurs in PKU. Adult subjects with
PKU will undergo EEG and comprehensive MRI evaluations, including a novel method of MR
spectroscopy to determine brain phenylalanine levels. In addition, they will receive
neurological and neuropsychological examinations and dietary evaluation.
Inclusion Criteria:
1. Adult with classic PKU who has been seen at one of the hospitals collaborating in
this study
2. Age 18-55 years
3. Medical Records available that include genotype and blood phenylalanine levels during
the first 6 years of life. (We have over 300 patients with PKU with genotypes in our
clinic, of whom about half are adults.)
4. Capable of providing informed consent
5. Able to undergo MRI procedures without sedating medication
6. Does not have metal implants
7. Not currently on Kuvan, Large Neutral Amino Acid therapy or involved in any clinical
trials.
-
Exclusion Criteria:
1. Mild PKU or mild hyperphenylalaninemia
2. Less than 18 years old or great than 55 years old
3. No medical records available for the first 6 years of life
4. No record of genotype
5. Not capable of providing informed consent
6. Not able to undergo MRI without sedating medication
7. Has metal implants
8. Currently taking Kuvan, Large Neutral Amino Acid therapy or involved in any clinical
trial
-
We found this trial at
1
site
Boston Children's Hospital Boston Children's Hospital is a 395-bed comprehensive center for pediatric health care....
Click here to add this to my saved trials
